Literature DB >> 18818963

ERG evaluation of daily, high-dose sildenafil usage.

Christopher I Zoumalan1, Roham T Zamanian, Ramona L Doyle, Michael F Marmor.   

Abstract

PURPOSE: Sildenafil can cause transient, mild ERG changes in healthy individuals taking large single doses. Although the drug was originally intended for intermittent use in erectile dysfunction, it has now been approved for chronic use in subjects with pulmonary arterial hypertension (PAH). The purpose of our study is to investigate possible ERG changes in subjects using large doses of sildenafil on a chronic daily basis.
METHODS: We examined five subjects with PAH taking sildenafil daily for 1-4 years. Full-field electroretinogram (ERG), multifocal ERG (mfERG), and color testing were performed. Three of the subjects returned on a later date for challenge off and on the medication.
RESULTS: On chronic daily sildenafil, color vision testing was normal, and ERG and mfERG amplitudes were normal; however, cone implicit times on drug were modestly lengthened. There were no consistent full-field ERG changes when off the drug, but the mfERG showed a small amplitude increase and implicit time decrease, which returned 1 h after re-dosing.
CONCLUSION: There was a modest lengthening of cone implicit time on chronic daily doses of sildenafil and a hint that some of these changes may be reversible in the short term. It does not appear that chronic sildenafil usage at these dosage levels is seriously toxic or threatening to vision.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818963     DOI: 10.1007/s10633-008-9148-3

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  17 in total

1.  Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram.

Authors:  J K Luu; A V Chappelow; T J McCulley; M F Marmor
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

2.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

Review 3.  Combination therapy and new types of agents for pulmonary arterial hypertension.

Authors:  Dermot S O'Callaghan; Dermot O'Callaghan; Sean P Gaine
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

4.  Dose-dependency and time-course of electrophysiologic short-term effects of VIAGRA: a case study.

Authors:  Herbert Jägle; Christine Jägle; Ludwig Sèrey; Lindsay T Sharpe
Journal:  Doc Ophthalmol       Date:  2005 Mar-May       Impact factor: 2.379

5.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

6.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

7.  Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Authors:  Roland Fries; Kaveh Shariat; Hubertus von Wilmowsky; Michael Böhm
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

8.  Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.

Authors:  Howard D Pomeranz; Kyle H Smith; William M Hart; Robert A Egan
Journal:  Ophthalmology       Date:  2002-03       Impact factor: 12.079

9.  Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose.

Authors:  Andrew R McCullough; Christopher P Steidle; Brian Klee; Li-Jung Tseng
Journal:  Urology       Date:  2008-04       Impact factor: 2.649

10.  Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa.

Authors:  M Danciger; J Blaney; Y Q Gao; D Y Zhao; J R Heckenlively; S G Jacobson; D B Farber
Journal:  Genomics       Date:  1995-11-01       Impact factor: 5.736

View more
  11 in total

1.  Visual impairment with possible macular changes after a high dose of sildenafil in a healthy young woman.

Authors:  Yun-Yun Li; Ya-Jie Yu; Xi-Pu Liu; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

2.  Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension.

Authors:  Licia Matieli; Adriana Berezovsky; Solange Rios Salomão; Norma Allemann; Elisabeth Nogueira Martins; Flavio E Hirai; Jaquelina Ota-Arakaki; Maira S A Morales; Denise de Freitas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-19       Impact factor: 3.117

3.  cGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodents.

Authors:  Santiago A Plano; Patricia V Agostino; Horacio O de la Iglesia; Diego A Golombek
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

4.  Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.

Authors:  Barbara M Wirostko; Charles Tressler; Lie-Ju Hwang; Gary Burgess; Alan M Laties
Journal:  BMJ       Date:  2012-02-21

5.  A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.

Authors:  Henri Leinonen; Cheng Cheng; Marja Pitkänen; Christopher L Sander; Jianye Zhang; Sama Saeid; Teemu Turunen; Alyaa Shmara; Lan Weiss; Lac Ta; Timothy Ton; Ari Koskelainen; Jesse D Vargas; Virginia Kimonis; Krzysztof Palczewski
Journal:  J Pharmacol Exp Ther       Date:  2021-04-30       Impact factor: 4.402

Review 6.  Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.

Authors:  Marilita M Moschos; Eirini Nitoda
Journal:  Drug Des Devel Ther       Date:  2016-10-19       Impact factor: 4.162

7.  Human Retinal Organoids Provide a Suitable Tool for Toxicological Investigations: A Comprehensive Validation Using Drugs and Compounds Affecting the Retina.

Authors:  Birthe Dorgau; Maria Georgiou; Alexander Chaudhary; Marina Moya-Molina; Joseph Collin; Rachel Queen; Gerrit Hilgen; Tracey Davey; Philip Hewitt; Michael Schmitt; Stefan Kustermann; Francois Pognan; David H Steel; Evelyne Sernagor; Lyle Armstrong; Majlinda Lako
Journal:  Stem Cells Transl Med       Date:  2022-03-17       Impact factor: 7.655

8.  Prolonged, longstanding, ultra-high-dose abuse of sildenafil.

Authors:  T S Sathyanarayana Rao; V Arun Kumar; Rajesh Raman; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2015 Jul-Sep       Impact factor: 1.759

9.  Evaluation of cone function by a handheld non-mydriatic flicker electroretinogram device.

Authors:  Natsuko Nakamura; Kaoru Fujinami; Yoshinobu Mizuno; Toru Noda; Kazushige Tsunoda
Journal:  Clin Ophthalmol       Date:  2016-06-30

Review 10.  Visual Side Effects Linked to Sildenafil Consumption: An Update.

Authors:  Eva Ausó; Violeta Gómez-Vicente; Gema Esquiva
Journal:  Biomedicines       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.